Claris Lifesciences drops after block deals

Claris Lifesciences lost 2.79% to Rs 191.80 at 15:10 IST on BSE after two block deals aggregating 12 lakh shares were executed on BSE at Rs 200 per share at 14:33 IST.

One block deal was of 7 lakh shares while the other deal was of 5 lakh shares. The two block deals constitute 1.88% of Claris Lifesciences' equity.

Meanwhile, the S&P BSE Sensex was down 265.61 points or 1.43% at 18,276.59.

On BSE, 12.35 lakh shares were traded in the counter as against average daily volume of 58,394 shares in the past one quarter.

The stock hit a high of Rs 200 and a low of Rs 191.25 so far during the day. The stock had hit a 52-week low of Rs 147.20 on 18 May 2012. The stock had hit a record high of Rs 292.20 on 5 December 2012.

The stock had outperformed the market over the past one month till 11 April 2013, surging 5.9% compared with the Sensex's 5.62% fall. The scrip had, however, underperformed the market in past one quarter, declining 5.73% as against Sensex's 5.7% fall.

The small-cap company has equity capital of Rs 63.82 crore. Face value per share is Rs 10.

Claris Lifesciences' consolidated net profit declined 27.3% to Rs 25.19 crore on 3.9% growth in net sales to Rs 193.59 crore in Q4 December 2012 over Q4 December 2011.

Claris Lifesciences is a pharmaceutical company in the sterile injectables business with a market presence in 98 countries worldwide. The company manufactures and markets products across multiple markets, and therapeutic segments. A significant majority of these products are generic drugs that are capable of being directly injected into the human body and are predominantly used in the treatment of critical illnesses. The customer base primarily includes government and private hospitals, aid agencies, and nursing homes.

Powered by Capital Market - Live News